Correction to: The Journal of Antibiotics
https://doi.org/10.1038/s41429-023-00629-8 published online 08 June 2023
The authors of the above article have noticed that prodrug contezolid acefosamil (3) was incorrectly stated as being approved rather than contezolid (4). This has been corrected throughout the review.
The changes are below:
In the sentence in the third paragraph of the introduction beginning “The new antibacterial drugs approved since the previous 2019 review…”, “contezolid acefosamil (3)” should have been “contezolid (4)”.
In Table 1, the drug name “contezolid acefosamil (3) (prodrug)” should have been “contezolid (4)”, without “(prodrug)”.
In the sentence beginning “Since the 2019 review…”, in paragraph 2 of the section “Antibacterial drugs launched from January 2013 to December 2022”, “contezolid acefosamil (3)” should have been “contezolid (4)”.
In the fourth paragraph of the section “Antibacterial drugs launched from January 2013 to December 2022”, several changes have been made. In the first sentence, “Contezolid acefosamil (3)” has been changed to “Contezolid (4)”, “(Youxitai, MRX-4, po)” has been changed to “(Youxitai, MRX-1, IV)”, and the word “prodrug” has been removed. In the third sentence, “(MRX-1)” has been removed, and “3” has been changed to “contezolid acefosamil (3)”. In the fourth sentence, “The prodrug” has been changed to “The prodrug 3”.
In the “Conclusion and outlook” section, in the sentence beginning “There were only two new small molecule antibacterial drugs…”, “the oxazolidinone contezolid acefosamil (3)” should have read “the oxazolidinone contezolid (4)”.
In addition, there was also an error in the “New antibacterial pharmacophore analysis” section where it was stated that gepotidacin (10) inhibited GyrB and not GyrA. The mode of action of gepotidacin (10) is correctly described elsewhere in the review. GyrB has been corrected to GyrA.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Butler, M.S., Henderson, I.R., Capon, R.J. et al. Correction: Antibiotics in the clinical pipeline as of December 2022. J Antibiot 77, 71 (2024). https://doi.org/10.1038/s41429-023-00671-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41429-023-00671-6
